A three-year naturalistic follow-up of patients receiving clozapine: Report from India

International Journal of Psychiatry in Clinical Practice

Volumn 6, Issue 3, 2002, Pages 167-171

  Srivastava, Shrikant ^a   Agarwal, Ak ^a   Sharma, Mukul ^a  

^a QUEEN ELIZABETH PSYCHIATRIC HOSPITAL   (United Kingdom)

Author keywords

Clozapine monotherapy; Indian subcontinent; Low dose requirement; Treatment resistant schizophrenia

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPERSALIVATION; HYPOTENSION; INDIA; LONG TERM CARE; MALE; MENTAL DISEASE; OBSESSION; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOCIAL INTERACTION; TACHYCARDIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0036733192     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/136515002760276108     Document Type: Article

References (26)

1. Clozapine Study Group (1993) The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Br J Psychiatry 35: 8-15.
2. Rosenheck R, Dunn L, Peszke M et al (1999) Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 156: 88-93.
3. Wahlbeck K, Cheine M, Essali A et al (1999) Evidence of clozapine effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. Am J Psychiatry 156: 990-99.
4. Juul Povlsen U, Noring U, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 71: 176-85.
5. Lindstrom LH (1988) The effect of long-term treatment of clozapine in schizophrenia: a retrospective study of 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 77: 524-29.
6. Lieberman JA, Safferman AZ, Pollack S et al (1994) Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151: 1744-52.
7. Janet T, Peter J (1998) Does participation in psychosocial treatment augment the benefit of clozapine? Acta Psychiatr Scand 55: 618-25.
8. World Health Organization (1992) The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. WHO, Geneva
9. Agarwal AK, Sharma M, Srivastava S et al (1997) An open clinical trial with clozapine in treatment-resistant schizophrenics. Indian J Psychiatry 39: 70-75.
10. Overall JE, Gorham DR (1960) The Brief Psychiatric Rating Scale. Psychol Rep. 10: 791-812.
11. Kay SG, Opier LD, Lindenmayer JR (1988) Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenia. Psychiatry Res 23: 91-110.
12. Buchanan RW, Carpenter Jr WT (2000) Schizophrenia: Introduction and overview. In: Sadock BJ, Sadock VA, eds. Comprehensive Textbook of Psychiatry (7th edn) 1096-1109. Lippincott, Williams & Wilkins, Philadelphia.
13. Liebrman JA (1999) Pathophysiologic mechanism in the pathogenesis and clinical course of schizophrenia. J Clin Psych 60 (Suppl 12): 9-12.
14. Kane JM, Honigfeld G, Singer J et al (1988) Clozapine for the treatment-resistant schizophrenics. A double blind comparison with chlorpromazine. Arch Gen Psychiatr 45: 789-96.
15. Essock SM, Hargreaves WA, Dohm F et al (1996) Clozapine eligibility among state hospital patients. Schizophr Bull 22: 15-25.
16. Conley RR, Carpenter WT, Tamminga CA (1997) Time to clozapine in a standardized trial. Am J Psychiatry. 154: 1243-47.
17. Buchanan RW, Breier A, Kirkpatrick B et al (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without deficit syndrome. Am J Psychiatry 155: 751-60.
18. Hasegawa M, Gutierrez-Esteinou R, Way L et al (1993) Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. Psychopharmacology (Berl.) 13: 383-90.
19. Kronig MH, Munne RA, Szymanski S (1995) Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 152: 179-82.
20. Vanderzwagg C, McGee M, McEvoy JP et al (1996) Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 153: 1579-84.
21. Fleishhakker WW, Hummer M, Kurz M et al (1994) Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 55: (Suppl 3): 78-81.
22. World Health Organization (1973) Report of the International Pilot Study of Schizophrenia (Vol. 1). WHO, Geneva.
23. Leff J, Sartorius N, Jablensky A et al (1992) The International Pilot Study of Schizophrenia: five-year follow-up findings. Psychol Med 22: 131-45.
24. Sartorius N, Jablensky A, Korten A et al (1986) Early manifestations and contact incidence of schizophrenia. Psychol Med 16: 909-28.
25. Matsuda KT, Cho MC, Lin KM et al (1996) Clozapine dosage, serum levels, efficacy and side effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 32: 253-7.
26. Ramirez LF (1996) Ethnicity and psychopharmacology in Latin America. Mt Sinai J Med (NY) 63: 330-1.